NasdaqGM:CLSD

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$267.2m

Last Updated

2021/06/18 00:26 UTC

Data Sources

Company Financials +

Executive Summary

Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. More Details


Snowflake Analysis

Excellent balance sheet and slightly overvalued.

Share Price & News

How has Clearside Biomedical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CLSD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: CLSD's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

49.2%

CLSD

0.2%

US Pharmaceuticals

0.2%

US Market


1 Year Return

132.0%

CLSD

16.4%

US Pharmaceuticals

39.7%

US Market

Return vs Industry: CLSD exceeded the US Pharmaceuticals industry which returned 21.2% over the past year.

Return vs Market: CLSD exceeded the US Market which returned 43.1% over the past year.


Shareholder returns

CLSDIndustryMarket
7 Day49.2%0.2%0.2%
30 Day95.0%1.0%2.5%
90 Day69.3%5.5%5.9%
1 Year132.0%132.0%21.1%16.4%41.9%39.7%
3 Year-55.0%-55.0%36.2%24.9%59.7%49.8%
5 Year-32.8%-32.8%48.6%29.4%125.6%100.3%

Long-Term Price Volatility Vs. Market

How volatile is Clearside Biomedical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Clearside Biomedical undervalued compared to its fair value and its price relative to the market?

46.2%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CLSD ($3.02) is trading below our estimate of fair value ($8.63)

Significantly Below Fair Value: CLSD is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CLSD is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: CLSD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CLSD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CLSD is overvalued based on its PB Ratio (10.2x) compared to the US Pharmaceuticals industry average (3.3x).


Future Growth

How is Clearside Biomedical forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-6.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLSD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CLSD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CLSD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CLSD's revenue (33.2% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: CLSD's revenue (33.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CLSD's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Clearside Biomedical performed over the past 5 years?

1.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CLSD is currently unprofitable.

Growing Profit Margin: CLSD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CLSD is unprofitable, but has reduced losses over the past 5 years at a rate of 1.9% per year.

Accelerating Growth: Unable to compare CLSD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CLSD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (0.3%).


Return on Equity

High ROE: CLSD has a negative Return on Equity (-133.35%), as it is currently unprofitable.


Financial Health

How is Clearside Biomedical's financial position?


Financial Position Analysis

Short Term Liabilities: CLSD's short term assets ($26.7M) exceed its short term liabilities ($10.3M).

Long Term Liabilities: CLSD's short term assets ($26.7M) exceed its long term liabilities ($539.0K).


Debt to Equity History and Analysis

Debt Level: CLSD is debt free.

Reducing Debt: CLSD has no debt compared to 5 years ago when its debt to equity ratio was 102%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CLSD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CLSD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Clearside Biomedical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CLSD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CLSD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CLSD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CLSD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CLSD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

George Lasezkay (68 yo)

2.17yrs

Tenure

US$1,371,007

Compensation

Dr. George M. Lasezkay, Pharm.D, & J.D. has been Chief Executive Officer at Clearside BioMedical, Inc. since March 2020, serves as President since March 1, 2020 and served as its Interim Chief Executive Of...


CEO Compensation Analysis

Compensation vs Market: George's total compensation ($USD1.37M) is above average for companies of similar size in the US market ($USD1.03M).

Compensation vs Earnings: George's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CLSD's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: CLSD's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.3%.


Top Shareholders

Company Information

Clearside Biomedical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Clearside Biomedical, Inc.
  • Ticker: CLSD
  • Exchange: NasdaqGM
  • Founded: 2011
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$267.165m
  • Shares outstanding: 57.58m
  • Website: https://www.clearsidebio.com

Number of Employees


Location

  • Clearside Biomedical, Inc.
  • 900 North Point Parkway
  • Suite 200
  • Alpharetta
  • Georgia
  • 30005
  • United States

Listings


Biography

Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/18 00:26
End of Day Share Price2021/06/17 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.